GlassScriptPhysician profile
Brian S Geller
NPI 1558375329
$5,081.80
in general payments reported to CMS, 2019-2025
31 companies · $596 in 2025
The $596 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $615 · 2021: $866 · 2022: $554 · 2023: $883 · 2024: $953 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,431.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,018.02 | 2019-2025 | |
| Pfizer INC. | $619.80 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $452.68 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $432.81 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $358.31 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $289.33 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.95 | 2019-2023 | Jardiance |
| Esperion Therapeutics, INC. | $209.00 | 2020-2025 | Nexletol |
| Amgen INC. | $203.39 | 2019-2024 | Repatha |
| Amarin Pharma, INC. | $146.51 | 2019-2021 | |
| Boston Scientific Corporation | $142.91 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Cvrx, INC. | $116.33 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.38 | 2019-2022 | |
| Abbott Laboratories | $105.79 | 2020-2023 | Mitraclip, Cardiomems |
| Novo Nordisk INC | $90.98 | 2024-2025 | Ozempic, Wegovy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $66.50 | 2019-2023 | Farxiga |
| Chiesi USA, INC. | $52.86 | 2019-2020 | |
| Daiichi Sankyo INC. | $45.83 | 2024 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $44.58 | 2019-2024 | Evkeeza |
| Edwards Lifesciences Corporation | $38.85 | 2019 | |
| Lundbeck LLC | $35.19 | 2019-2020 | |
| Recor Medical INC | $31.10 | 2025 | Paradise Ultrasound Renal Denervation System |
| Arbor Pharmaceuticals, INC. | $27.73 | 2021 | |
| Baxter Healthcare | $26.93 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Philips North America LLC | $24.13 | 2024 | (Cm9) Amb Mon & Diag Und |
| Glaxosmithkline, LLC. | $23.74 | 2025 | Arexvy, Shingrix |
| Vifor Pharma, INC. | $21.44 | 2019 | |
| Medtronic, INC. | $21.00 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.96 | 2024 | Amvuttra |
| Heartflow, INC. | $15.46 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $15.31 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.